Fat Tissue Has Its Own Appetite Control System Involving Melanocortin 3 Receptors
The melanocortin 3 receptor in fat tissue is regulated by ghrelin and leptin, and its disruption in obesity makes it a potential new drug target.
Quick Facts
What This Study Found
The melanocortin 3 receptor in adipose tissue is regulated by ghrelin and leptin, and its disruption in obesity suggests it could be a therapeutic target for metabolic disease.
Key Numbers
Expression of NPY/melanocortin receptors was assessed in visceral adipose tissue of individuals with obesity and altered metabolism.
How They Did This
Analysis of NPY/melanocortin receptor expression in visceral fat tissue from individuals with obesity and metabolic dysfunction, combined with mechanistic studies.
Why This Research Matters
Most obesity treatments target the brain. Finding that fat tissue has its own appetite-related signaling system opens an entirely new avenue for treatment.
The Bigger Picture
Discovering appetite-related signaling in fat tissue itself is surprising. If fat tissue actively participates in metabolic regulation through its own melanocortin receptors, targeting these peripheral receptors could provide obesity treatments without brain side effects.
What This Study Doesn't Tell Us
Early-stage research characterizing receptor expression. Therapeutic targeting of MC3R in fat tissue has not been tested yet.
Questions This Raises
- ?Could MC3R agonists in fat tissue improve metabolic health without CNS effects?
- ?Is the peripheral melanocortin system a cause or consequence of obesity?
Trust & Context
- Key Stat:
- MC3R in fat tissue The melanocortin 3 receptor, previously known mainly in the brain, was found to be active and hormonally regulated in visceral fat tissue
- Evidence Grade:
- Rated preliminary: novel finding characterizing receptor expression in human fat tissue with mechanistic cell studies. No therapeutic testing yet.
- Study Age:
- Published in 2024. A new discovery about peripheral metabolic signaling that could influence future drug development.
- Original Title:
- The adipose tissue melanocortin 3 receptor is targeted by ghrelin and leptin and may be a therapeutic target in obesity.
- Published In:
- Molecular and cellular endocrinology, 594, 112367 (2024)
- Authors:
- Rosendo-Silva, Daniela, Lopes, Eduardo, Monteiro-Alfredo, Tamaeh, Falcão-Pires, Inês, Eickhoff, Hans, Viana, Sofia, Reis, Flávio, Pires, Ana Salomé, Abrantes, Ana Margarida, Botelho, Maria Filomena, Seiça, Raquel, Matafome, Paulo
- Database ID:
- RPEP-09170
Evidence Hierarchy
Frequently Asked Questions
Does fat tissue have its own appetite system?
This study found that visceral fat has melanocortin 3 receptors regulated by hunger and satiety hormones, suggesting fat tissue actively participates in metabolic signaling.
Could this lead to new obesity drugs?
Potentially — targeting MC3R in fat tissue could provide metabolic benefits without brain-related side effects common to many obesity drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09170APA
Rosendo-Silva, Daniela; Lopes, Eduardo; Monteiro-Alfredo, Tamaeh; Falcão-Pires, Inês; Eickhoff, Hans; Viana, Sofia; Reis, Flávio; Pires, Ana Salomé; Abrantes, Ana Margarida; Botelho, Maria Filomena; Seiça, Raquel; Matafome, Paulo. (2024). The adipose tissue melanocortin 3 receptor is targeted by ghrelin and leptin and may be a therapeutic target in obesity.. Molecular and cellular endocrinology, 594, 112367. https://doi.org/10.1016/j.mce.2024.112367
MLA
Rosendo-Silva, Daniela, et al. "The adipose tissue melanocortin 3 receptor is targeted by ghrelin and leptin and may be a therapeutic target in obesity.." Molecular and cellular endocrinology, 2024. https://doi.org/10.1016/j.mce.2024.112367
RethinkPeptides
RethinkPeptides Research Database. "The adipose tissue melanocortin 3 receptor is targeted by gh..." RPEP-09170. Retrieved from https://rethinkpeptides.com/research/rosendo-silva-2024-the-adipose-tissue-melanocortin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.